[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Gynaecomastia is when males of any age develop breasts. Pubertal gynaecomastia refers specifically to the physiological ...

While progestins, tamoxifen, and progestins alternating with tamoxifen have been well established for decades, CDK4/6 ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Discover the groundbreaking patent by Prelude Therapeutics Inc for Formula I compounds targeting CDK2, CDK4, and CDK6 in cancer treatment. Explore the potential of these innovative therapies now!

IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial ...

Sermonix Pharma receives Chinese approval of IND application for lasofoxifene: Columbus, Ohio Saturday, June 8, 2024, 14:00 Hrs [IST] Sermonix Pharmaceuticals LLC, a privately hel ...

Menopause can be a challenging phase of life, impacting not just physical health but also emotional well-being. Navigating ...

Most of them seemed to think debilitating pain is part of being female. This pain is so bad that it is incapacitating. I've missed work and school because of it. I would throw up anything that I tried ...

Anastrozole was the first aromatase inhibitor (a drug that blocks estrogen production in the body) to be approved for cancer therapy. The 1980s saw improvements in surgery options for people with ...

Verastem stock dips 70% due to updated clinical data, but trading opportunity may arise with FDA's rolling submission ...

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, looks at options for a patients with hormone receptor–positive, ...